Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Company Type
Last funding type
IPO status
Contacts
location
Similar Companies1000
Tissue Regenix
Tissue Regenix commercializes innovative technologies in regenerative medicine.
Sector
Subsector
Location
total rounds
total raised
Spiderwort
Spiderwort is a tissue engineering company that develops transformative biomaterials for repairing and regenerating human tissues.
Sector
Subsector
Location
total rounds
total raised
Huanova
Huanova develops innovative medical solutions for organ regeneration and tissue repair.
Sector
Subsector
Location
Biocell
The company develops and sells innovative medical therapeutics, with a focus on advanced wound care and tissue regeneration.
Sector
Subsector
Keywords
Location
total rounds
M&A Details1
Financials
Funding Rounds2
Number of Funding Rounds
Money Raised
Their latest funding was raised on 01.03.2006. Their latest investor DeNovo Ventures. Their latest round Series B
DeNovo Ventures
DeNovo Ventures invests in medical devices and biotech companies for high returns and clinical impact.
Sector
Subsector
Location
count Of Investments
count Of Exists
Co-Investors
Investors1
Number of lead investors
Number of investors
DeNovo Ventures
DeNovo Ventures invests in medical devices and biotech companies for high returns and clinical impact.
Sector
Subsector
Location
count Of Investments
count Of Exists
Frederick Dotzler
Fred co-founded De Novo in 2000. Prior to De Novo, he was a Managing General Partner of Medicus Venture Partners (“Medicusâ€), which he founded in 1989. Medicus was an early stage investor in companies such as Anergen, Applied Molecular Evolution, Biosite Diagnostics, Inhale Therapeutic Systems (now Nektar), Omnicell and Tularik. Prior to Medicus, he was a General Partner with Crosspoint Venture Partners for 5 years, where he invested in life sciences companies. Prior to joining Crosspoint, Fred served in executive positions in finance, marketing, sales, manufacturing and business development for companies selling pharmaceuticals (Searle), medical instruments (Merrimack), biotechnology research tools (Millipore), and computers (IBM). Fred earned an MBA from the University of Chicago, a Masters equivalent in Economics from the University of Louvain, Belgium and a BS in Engineering from Iowa State University, where he received a Professional Achievement Citation in Engineering in 2000. He is a member of the Advisory Board of the Journal of Private Equity. Fred sits on the boards of Bayhill Therapeutics, Cartilix, HemaQuest, Talima, SenoRx (NASDAQ: SENO) and Vitreo Retinal Technologies. Fred also represented De Novo on investments in Microvention, Oncomed and Renovis.
current job
People
Founders2
Frank Huerta
Mr. Huerta is responsible for the vision and strategic direction of TransLattice. He started his career in engineering and product development at Hughes Aircraft Company, Santa Barbara Research Center. He then served in product management roles at Seagate Software as well as VeriFone, Inc. Mr. Huerta was the director of business development for Exodus Communications where he focused on mergers and acquisitions. He was a co-founder and the CEO of Recourse Technologies, where he raised nearly $40M from leading venture capitalists and corporations. Recourse was purchased by Symantec Corporation for $135M in cash, and Mr. Huerta then served as a vice president at Symantec for over a year. He serves on the board of the Arthritis Foundation of Northern California and Cate School Board of Trustees. Mr. Huerta has an MBA from the Stanford Graduate School of Business and an undergraduate degree in physics from Harvard University, graduating cum laude.
current job
organization founded
Frank Huerta
Jennifer H. Elisseeff
Jennifer H. Elisseeff is the Jules Stein Professor at Wilmer Eye Institute. Jennifer Elisseeff attended Massachusetts Institute of Technology.
current job
organization founded
Jennifer H. Elisseeff